Media Releases

For all media enquiries, please contact

Q-Pharm Pty Limited appoints new CEO

Q-Pharm, one of Australia’s leading early-phase clinical research organisations, today announced that Dr Tufail Syed has been appointed as the new CEO of the company.

The Q-Pharm board has thanked interim CEO Michael Creevey for his excellent support and leadership during the transition period prior to Dr Syed’s appointment.

Dr Syed has 17 years of clinical research experience gained in academia, large pharmaceutical companies and global clinical research organisations.

Most recently, he held the role of regional head of Global Testing Services for the Asia-Pacific at Covance. Prior to that, Dr Syed held executive and senior leadership roles at Medpace Inc. and Eli Lilly and Company.

He trained as a physician in India before relocating to the United States, where he did further training and worked as a medical researcher. He received an MBA from Rutgers Business School in New Jersey.

“Q-Pharm has proved itself to be a reliable partner to the clinical research enterprise over the last 15 years through its high quality, safety, and operational excellence,” Dr Syed said.

“I am delighted to join a best-in-class clinical research team that is dedicated to providing exceptional services to our clients and improving lives through clinical research.”

The chairman of the Q-Pharm board, Professor Frank Gannon, said Dr Syed brought a rich and diverse set of skills, knowledge and experience to the role.

“I am delighted to welcome Tufail Syed as we enter a new and ambitious phase of the company,” Professor Gannon said.

“Under his leadership, Q-Pharm will maintain its focus on reliability and quality, while expanding our activities to new markets and offerings.

“Dr Syed brings a great combination of skills and experience, which will ensure that these goals are reached.”

About Q-Pharm:

Founded in 2002, Q-Pharm has built an enviable reputation in the recruitment and conduct of early-phase clinical trials. Q-Pharm’s foundations in bioequivalence, vaccine, and disease challenge models in a broad range of healthy volunteer and patient-based trials have grown into widely acknowledged expertise. Q-Pharm has conducted more than 400 clinical trials in its state-of-the-art facilities located at Brisbane’s QIMR Berghofer Medical Research Institute. Q-Pharm provides comprehensive, high-quality services for its clients, and conducts clinical trials in accordance with all applicable national and international safety standards and guidelines. While safety and quality remain the heart of the business, Q-Pharm proactively seeks innovative and intelligent growth opportunities in the area of clinical trials.